Neogenix Oncology, Inc. (Neogenix) announced today that it is entering a research collaboration with IRCCS San Raffaele Pisana in Rome, Italy led by Dr. Fiorella Guadagni. This research agreement reflects the ongoing expansion of Neogenix's collaboration strategy and aims to accelerate the development of a rapid antibody based diagnostic test. The opportunity to access a broad range of clinical samples will provide clinical data to support both a stand-alone and companion diagnostic approach within Neogenix.

"This international collaboration may lead to important advances in diagnosing cancer and will strengthen and validate our ongoing clinical program. We are pleased to partner with Dr. Guadagni and the scientific investigators at San Raffaele Pisana on this important diagnostic research," said Neogenix Chief Executive Officer, Philip M. Arlen, MD.

"We are very enthusiastic to be part of this important area of research which will fortify both laboratories and support our collaboration in the field of cancer diagnostics. I have personally known Dr. Philip Arlen since my tenure at NIH and we have always had a strong scientific relationship. Our longstanding collaboration will be reinforced and will strengthen our international relationship," said Dr. Fiorella Guadagni MD, PhD, Chief Department of Laboratory Medicine and Advanced Biotechnologies at the IRCCS San Raffaele Pisana, Rome, Italy.